or buy back some stock... this would not only keep the shorts guessing but also signal management's confidence in the firm going forward.
The way i see ACR at the moment is a fully funded biotech option - IF (and thats a big IF) they can actually come up with another application / product from their pipeline, the upside could be large (noting that historically ACR has struggled to commercialise much outside of Axiron).
If they can't commercialise anything new, the downside is also limited - as based on the Axiron cashflows alone this thing is worth at least $1 per share (not counting any further milestones and limited international expansion).
Lets see what that new CEO can do in the new product space...
ACR Price at posting:
$1.05 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)